RALEIGH, N.C., June 24, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), today announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk. Data in the study published in Atherosclerosis demonstrated that high-risk patients who achieved a low LDL-P level experienced a 22-25 percent reduction in CVD risk compared to high-risk patients that achieved a low LDL-C level.
"Data from multiple epidemiological studies have suggested that LDL particle measurements are a better predictor of cardiovascular events than LDL cholesterol concentrations, particularly in patients whose LDL-P and LDL-C levels are dissimilar," noted study co-author Michael Grabner, PhD, of HealthCore, Inc. in Wilmington, Del. "We now have real-world evidence from a large-scale study of commercially insured patients to support the use of LDL-P measurement as an LDL management tool, based on the more favorable clinical outcomes we observed in patients achieving target LDL-P levels, compared to LDL-C targets."
The study was sponsored by LipoScience and jointly designed by LipoScience and HealthCore, with clinical input from Peter P. Toth, MD, PhD, Director of Preventive Cardiology at CGH Medical Center in Sterling, Ill. and Terry A. Jacobson, MD, Professor of Medicine at Emory University, Atlanta. Results were previously presented in poster sessions at the Scientific Sessions of the American Heart Association in November 2013 and the recent 63rd American College of Cardiology Scientific Sessions in Washington, D.C.
Grabner and colleagues conducted a claims analysis among high-risk patients identified from the HealthCore Integrated Research DatabaseSM (HIRD), which contains eligibility, medical and pharmacy claims for approximately 36 million members of Blue Cross and Blue Shield health plans across the U.S. High risk was determined based on the presence of established coronary heart disease (CHD), stroke, transient ischemic attack or diabetes mellitus. Among the 15,569 patients with LDL-P measurements in the study, the risk of a CHD event increased by approximately 4% for each 100 nmol/L increase in LDL-P level.
To improve comparability, patients treated to low LDL-P levels (<1000 nmol/L) were then matched to patients treated to low LDL-C levels (<100 mg/dL) with similar demographic and clinical characteristics. Among these matched cohorts, which included more than 4,000 high-risk patients, the investigators found that those who achieved target LDL-P levels received more aggressive lipid-lowering treatment than those reaching target LDL-C concentrations. Those treatment differences were associated with better outcomes (as measured by the reduction in CV event rates) over one to three years of follow-up.
"The HealthCore study is the first to demonstrate a real-world association between LDL particle levels and cardiovascular risk, while also demonstrating an association between attainment of a target LDL-P level and more aggressive lipid-lowering therapy," stated William C. Cromwell, MD, Chief Medical Officer of LipoScience. "The results suggest that using LDL cholesterol levels to guide treatment decisions may mask the need to consider changes in lipid-lowering therapy to help patients achieve appropriate reductions in LDL-P. The results also lend support to treatment guidelines recommending the use of LDL-P as a therapeutic target, as advocated by the American Association for Clinical Chemistry and the American Association of Clinical Endocrinologists."
About LipoScience, Inc. LipoScience, Inc. (NASDAQ: LPDX) is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile® test, the Company's first proprietary test, is the only FDA-cleared blood test that directly quantifies LDL particles and provides physicians and their patients with actionable information to personalize management of heart disease. To date, more than 11 million NMR LipoProfile tests have been ordered. LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for the management of cardiovascular disease.
The Vantera® Clinical Analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory. For further information on LipoScience, please visit www.liposcience.com.
About HealthCore, Inc. HealthCore, based in Wilmington, Del., is the clinical outcomes research subsidiary of WellPoint, Inc. HealthCore has a team of highly experienced researchers including physicians, biostatisticians, pharmacists, epidemiologists, health economists and other scientists who study the "real world" safety and effectiveness of drugs, medical devices and care management interventions. HealthCore offers insight on how to best use this data and communicates these findings to health care decision-makers to support evidence-based medicine, product development decisions, safety monitoring, coverage decisions, process improvement and overall cost-effective health care. For more information, go to www.healthcore.com.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: our industry, business strategy, goals and expectations concerning our future operations, performance or results, profitability, capital expenditures, liquidity and capital resources, timing or anticipated results of our FDA submissions and other financial and operating information. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward -looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
SOURCE LipoScience, Inc.